Illicium verum supplementation in patients with hypothyroidism

The effect of hydroalcoholic extract of Illicium verum on serum levels of thyroid hormones and stress oxidative index in patients with hypothyroidism: a double-blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141025019669N19

Enrollment

Registered

2021-09-24

Start date

2021-10-07

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypothyroidism. Other hypothyroidism

Interventions

Intervention 1: Intervention group: Hydroalcoholic extract of Illicium verum, Three 500 mg capsules per day for two months. Intervention 2: Control group: Three placebo capsules containing wheat flour

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients with hypothyroidism Patient 20-50 years old Having a body mass index less than 30 Consent signed by the patient

Exclusion criteria

Exclusion criteria: Pregnancy and lactation Infectious diseases, Inflammatory diseases, Diabetes, Cancer Taking antioxidant supplements in the last three months Drug use over the past three months, including diabetes, glucocorticoids, lipid-lowering drugs, and weight-loss drugs

Design outcomes

Primary

Measure	Time frame
Thyroxine hormone. Timepoint: Before the intervention and after the intervention. Method of measurement: ELISA.;Triiodothyronine hormone. Timepoint: Before the intervention and after the intervention. Method of measurement: ELISA.;Thyroid-stimulating hormone. Timepoint: Before the intervention and after the intervention. Method of measurement: ELISA.;Total antioxidant capacity. Timepoint: Before the intervention and after the intervention. Method of measurement: ELISA.;Malondialdehyde. Timepoint: Before the intervention and after the intervention. Method of measurement: ELISA.;Depression Anxiety and Stress. Timepoint: Before the intervention and after the intervention. Method of measurement: Depression Anxiety and Stress Scale (DASS-21).	—

Measure

Time frame

Thyroxine hormone. Timepoint: Before the intervention and after the intervention. Method of measurement: ELISA.;Triiodothyronine hormone. Timepoint: Before the intervention and after the intervention. Method of measurement: ELISA.;Thyroid-stimulating hormone. Timepoint: Before the intervention and after the intervention. Method of measurement: ELISA.;Total antioxidant capacity. Timepoint: Before the intervention and after the intervention. Method of measurement: ELISA.;Malondialdehyde. Timepoint: Before the intervention and after the intervention. Method of measurement: ELISA.;Depression Anxiety and Stress. Timepoint: Before the intervention and after the intervention. Method of measurement: Depression Anxiety and Stress Scale (DASS-21).

—

Secondary

Measure	Time frame
Body mass index. Timepoint: Before the intervention and after the intervention. Method of measurement: Using the formula (weight in kilograms divided by height in meters squared).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Khadem Haghighian

Qazvin University of Medical Sciences

khademnut@yahoo.com+98 28 3333 6001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026